Aldesleukin (Proleukin): A Comprehensive Monograph on a Foundational High-Dose Cytokine Immunotherapy

Executive Summary

Aldesleukin, a recombinant form of interleukin-2, represents a paradigm of high-risk, high-reward immunotherapy. As a potent cytokine, it non-specifically activates a broad and powerful anti-tumor immune response, leading to durable, complete remissions in a small but significant subset of patients with metastatic melanoma and renal cell carcinoma. This efficacy, however, is inextricably linked to a profile of severe, life-threatening toxicities, most notably Capillary Leak Syndrome, which necessitates administration in a specialized inpatient setting with intensive care support. This monograph provides an exhaustive analysis of Aldesleukin's complex pharmacology, its established and emerging clinical roles, the rigorous demands of its administration and safety management, and its regulatory history. It positions Aldesleukin not as an obsolete agent in the era of targeted therapies and checkpoint inhibitors, but as a formidable, albeit niche, therapeutic option whose unique mechanism continues to offer the potential for a cure in select patients.

Section 1: Introduction to Aldesleukin – A Recombinant Cytokine

1.1. Overview and Classification

Aldesleukin is a synthetic, highly purified protein that functions as a recombinant analogue of the endogenous human cytokine interleukin-2 (IL-2).[1] It is produced via recombinant DNA technology utilizing a genetically engineered strain of Escherichia coli that contains a modified version of the human IL-2 gene.[1] The resulting molecule, with a molecular weight of approximately 15,300 daltons, is chemically designated as des-alanyl-1, serine-125 human interleukin-2. These specific modifications—the deletion of the N-terminal alanine and the substitution of serine for cysteine at position 125—were engineered to enhance the molecule's stability and homogeneity compared to the native protein.[1]

Pharmacologically, Aldesleukin is classified as a biologic response modulator, an antineoplastic agent, and a pioneering form of immunotherapy known as cytokine therapy.[3] It is marketed under the brand name Proleukin.[3] A critical aspect of its clinical identity is its designation as a "high alert medication" by the Institute for Safe Medication Practices (ISMP).[6] This classification is reserved for drugs with a heightened risk of causing significant patient harm when used in error, a direct reflection of Aldesleukin's narrow therapeutic index and severe toxicity profile. This designation immediately frames the entire clinical discussion around the central theme that the drug's profound efficacy is inseparable from its profound and predictable toxicity, a duality that dictates every aspect of its use, from patient selection to the mandatory hospital setting for administration.

1.2. Therapeutic Rationale and Historical Context

The fundamental therapeutic principle of Aldesleukin is the administration of supraphysiologic, or high, doses of IL-2 to hyper-stimulate the patient's own immune system into mounting an effective anti-tumor response.[5] Also known as T-cell growth factor, IL-2 is a critical cytokine in the adaptive immune process, and by providing it in large quantities, the therapy aims to induce the proliferation, maturation, and enhanced cytotoxic activity of key immune effector cells, particularly T-lymphocytes and Natural Killer (NK) cells.[3] As a systemic therapy, Aldesleukin is administered intravenously and circulates through the bloodstream, enabling it to target and act upon metastatic cancer cells that have disseminated throughout the body.[8]

The development and subsequent regulatory approval of Aldesleukin in the early 1990s for metastatic renal cell carcinoma (1992) and metastatic melanoma (1998) represented a foundational moment in the field of immuno-oncology.[3] Long before the advent of modern checkpoint inhibitors and targeted therapies, Aldesleukin provided the first definitive proof-of-concept that pharmacologic manipulation of the immune system could induce durable, and in some cases complete, remissions of advanced cancers.[12] This established a new pillar of cancer treatment and paved the way for the development of the broader field of immunotherapy.

Table 1: Aldesleukin (Proleukin) At-a-Glance

Attribute	Description
Generic Name	Aldesleukin
Brand Name	Proleukin
Drug Class	Biologic Response Modulator, Immunotherapy (Cytokine) 4
Mechanism of Action	Recombinant Interleukin-2 (IL-2) receptor agonist 9
FDA-Approved Indications	Metastatic Renal Cell Carcinoma, Metastatic Melanoma 3
Key Boxed Warnings	Capillary Leak Syndrome, Neurologic Toxicity, Serious Infections 1
Administration Route	Intravenous (high-dose); Subcutaneous (low-dose); Intralesional 5
Required Setting	Hospital with available Intensive Care Unit (ICU) facilities 1

Section 2: Pharmacology and Mechanism of Action

2.1. Molecular Interaction with the Interleukin-2 Receptor (IL-2R)

Aldesleukin functions by mimicking the action of endogenous IL-2, binding directly to the IL-2 receptor (IL-2R) complex expressed on the surface of various immune cells, most notably T-lymphocytes and NK cells.[9] The IL-2R can assemble into three distinct configurations with varying affinities for IL-2. The low-affinity receptor consists only of the alpha subunit (), while the intermediate-affinity receptor is a dimer of the beta () and common gamma () subunits. The high-affinity receptor, which is critical for mediating the most potent biological responses at low cytokine concentrations, is a trimeric complex composed of all three subunits: , , and .[9] The binding of Aldesleukin to this receptor complex induces a critical conformational change, leading to the heterodimerization of the cytoplasmic domains of the beta and gamma chains. This physical association is the essential initiating step for the downstream cascade of intracellular signaling events.[14]

2.2. Intracellular Signaling Cascades

The activation of the IL-2R by Aldesleukin triggers a blunt but powerful engagement of specific molecular pathways that drive cellular responses. The primary and most well-characterized of these is the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway.[9] Upon receptor dimerization, Janus kinases JAK1 and JAK3 are recruited to the intracellular domains of the receptor chains and become phosphorylated, thereby activating their kinase function.[9] These activated JAKs, in turn, phosphorylate tyrosine residues on the IL-2R beta chain, creating docking sites for STAT (Signal Transducer and Activator of Transcription) proteins, primarily STAT5.[9] Once docked, the STAT5 proteins are themselves phosphorylated by the JAKs. This phosphorylation event causes the STAT5 proteins to detach from the receptor, form stable dimers, and translocate into the cell nucleus. Within the nucleus, these STAT5 dimers function as potent transcription factors, binding to specific DNA sequences to promote the expression of a suite of genes critical for lymphocyte proliferation, differentiation, survival, and effector function.[9]

In parallel to the JAK-STAT pathway, Aldesleukin also activates the phosphoinositide 3-kinase (PI3K)-AKT-mTOR signaling cascade.[9] This pathway is crucial for promoting cell survival by providing anti-apoptotic signals that prevent programmed cell death. Furthermore, it supports the significant metabolic reprogramming required to fuel the high energy and biosynthetic demands of rapidly proliferating lymphocytes, ensuring that the expanding army of immune cells has the necessary resources to sustain its growth and function.[9] The engagement of these powerful, fundamental signaling pathways explains the profound biological effects of Aldesleukin.

2.3. Immunological Consequences of Signaling

The downstream immunological consequences of these signaling cascades are profound, systemic, and dose-dependent. The administration of high-dose Aldesleukin results in a broad and non-specific activation of the cellular immune system, characterized by several key effects:

• Enhanced Lymphocyte Mitogenesis: Aldesleukin potently stimulates the rapid cell division and clonal expansion of T-cells (both  helper and  cytotoxic subsets) and NK cells.[1] This leads to a profound lymphocytosis observed in treated patients.
• Increased Cytotoxicity: The therapy significantly boosts the intrinsic cancer-killing capacity of cytotoxic T-lymphocytes (CTLs) and NK cells, enhancing their ability to recognize and lyse tumor cells.[1] This is mediated in part by increased production of cytotoxic granules containing perforin and granzymes.[13]
• Induction of Killer Cells: Aldesleukin promotes the differentiation of resting lymphocytes into highly potent, non-specific effector cells known as lymphokine-activated killer (LAK) cells, which can kill a broad range of tumor targets.[1]
• Secondary Cytokine Production: A crucial aspect of Aldesleukin's mechanism is the induction of a secondary cytokine cascade. The activated lymphocytes begin to produce and release a host of other pro-inflammatory cytokines, including interferon-gamma (IFN-), tumor necrosis factor (TNF), and interleukin-1 (IL-1).[1] This cascade further amplifies the immune response, recruiting other immune cells to the tumor site. However, this uncontrolled systemic release of inflammatory mediators is also the direct mechanistic cause of the severe toxicities associated with the therapy, often referred to as a "cytokine release syndrome" or, in its most severe form, Capillary Leak Syndrome.[9] This demonstrates that the drug's therapeutic action and its primary toxicities are not separate phenomena but are two outcomes of the same powerful biological process.

2.4. The Dichotomy of Immune Activation: Effector vs. Regulatory T-Cells

The immunomodulatory effects of Aldesleukin are not limited to activating anti-tumor cells. A more nuanced understanding of its mechanism reveals a critical dichotomy in its action. While high-dose Aldesleukin potently expands the populations of anti-tumor effector T-cells (), it also stimulates the proliferation of a distinct T-cell subset known as   regulatory T-cells ().[13] These  are functionally immunosuppressive and play a crucial role in maintaining self-tolerance and preventing autoimmunity; however, in the context of cancer, they can dampen the anti-tumor immune response and hinder therapeutic efficacy.

This dual action creates a biological paradox: the same cytokine that activates the anti-cancer immune response also activates the very cells designed to suppress it. The key to this paradox lies in the differential expression of the IL-2R.  constitutively express the high-affinity trimeric IL-2R (), making them exquisitely sensitive to even low concentrations of IL-2. In contrast, resting effector T-cells express only the intermediate-affinity receptor and must be activated to upregulate the high-affinity version.[13] This differential sensitivity is the basis for Aldesleukin's remarkable therapeutic plasticity. At the high doses used in oncology, Aldesleukin saturates all receptor types, leading to a massive expansion of both  and  populations. The net clinical outcome—tumor regression versus lack of response—may depend on the ultimate balance achieved between these opposing cell populations within the patient's tumor microenvironment.[13] Conversely, at the very low doses used in treating conditions like graft-versus-host disease, Aldesleukin can preferentially expand the highly sensitive  population, leveraging their immunosuppressive function to restore immune tolerance. This ability to use the same molecule for diametrically opposed therapeutic goals—potent immune stimulation versus targeted immune suppression—simply by modulating the dose, represents a sophisticated application of fundamental immunological principles.

Section 3: Pharmacokinetic Profile

3.1. Administration and Absorption

Aldesleukin is supplied as a sterile, lyophilized powder that requires reconstitution prior to administration.[2] For its primary oncologic indications of metastatic renal cell carcinoma and metastatic melanoma, the standard route of administration is a 15-minute intravenous (IV) infusion.[1] The drug is not orally bioavailable and must be given parenterally.[20]

Alternative routes of administration are employed for other indications or in different regulatory settings. Subcutaneous (SubQ) injection is utilized for lower-dose regimens, such as those investigated for chronic graft-versus-host disease or as was initially approved in Australia for renal cell carcinoma. The bioavailability following subcutaneous administration is estimated to be between 35% and 47%.[5] Intralesional injection has also been explored as a means to deliver high local concentrations of the drug directly into tumor tissue while minimizing systemic exposure and toxicity.[20]

3.2. Distribution, Metabolism, and Excretion

The pharmacokinetic profile of Aldesleukin is characterized by rapid distribution and clearance, which fundamentally dictates its intensive dosing schedule.

• Distribution: Following a short IV infusion, the drug distributes rapidly out of the plasma and into the extravascular space. Only about 30% of the administered dose remains detectable in the plasma shortly after the infusion is complete.[1] It primarily accumulates in well-perfused organs, including the lungs, liver, kidneys, and spleen.[20] The volume of distribution is relatively small, reported to be in the range of 4 to 7 liters.[20] Data regarding its ability to cross the blood-brain barrier are inconclusive.[20]
• Metabolism: The kidney is the principal site of Aldesleukin metabolism.[1] The drug is broken down into its constituent amino acids within the cells lining the proximal convoluted tubules.[1] This process is highly efficient, and there are no known active metabolites of the drug.[20]
• Excretion: Clearance of Aldesleukin from the circulation is rapid and is almost entirely mediated by the kidneys. This occurs through a dual mechanism of both glomerular filtration and peritubular extraction, which may help preserve clearance even in patients with rising serum creatinine levels.[1] Because the drug is metabolized within the renal tubules, minimal to no bioactive protein is excreted in the urine.[1] The elimination profile from the plasma is biphasic. Studies in cancer patients have shown a rapid initial distribution half-life of approximately 13 minutes, followed by a terminal elimination half-life of approximately 85 minutes.[1] This very short half-life is a critical pharmacokinetic property, as it necessitates the intensive, frequent dosing regimen (every 8 hours) required to maintain the supraphysiologic drug concentrations needed to drive a sustained immune assault on tumor cells. The body eliminates the drug so quickly that repeated infusions are essential for achieving the desired therapeutic effect.

Section 4: Clinical Efficacy and Therapeutic Applications

4.1. FDA-Approved Indication: Metastatic Renal Cell Carcinoma (mRCC)

Aldesleukin was first approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic renal cell carcinoma (mRCC) in 1992.[10] This landmark approval was based on an analysis of data from seven Phase II clinical trials involving 255 patients, which demonstrated an overall objective response rate (ORR) of 14%.[23] While this rate is modest by modern standards, the key finding was the profound durability of the responses in a subset of patients.

More contemporary data comes from the "Select" Trial (NCT00554515), a prospective, multi-center study designed to validate potential predictive biomarkers for response to high-dose (HD) IL-2 therapy. In this trial of 120 eligible patients with mRCC, HD IL-2 demonstrated an independently assessed ORR of 25% (30 of 120 patients), which was statistically significantly higher than the historical 14% rate. This included 3 complete responses (CR) and 27 partial responses (PR).[23]

The true hallmark of Aldesleukin therapy, and the primary justification for its continued use despite significant toxicity, is its unique ability to induce exceptionally durable, long-lasting remissions that can represent a functional cure. In the "Select" trial, 13 patients (11%) remained progression-free at 3 years, and the median overall survival (OS) for the entire cohort was an impressive 42.8 months.[23] This potential to produce a "tail on the curve" in survival plots, representing a small but significant fraction of patients who achieve long-term, treatment-free survival, distinguishes Aldesleukin from many other systemic therapies.

Historically, responses to immunotherapy in mRCC are most frequently observed in patients with clear cell histology.[23] While early attempts to create predictive models based on clinical or pathological features were unsuccessful in the "Select" trial, the study did uncover a novel and potentially important association: the ORR was positively correlated with tumor expression of programmed death-ligand 1 (PD-L1).[23] This finding suggests a potential mechanistic link between the older cytokine-based immunotherapy and the modern era of checkpoint inhibitors, and it warrants further validation as a predictive biomarker.

4.2. FDA-Approved Indication: Metastatic Melanoma

Following its approval for mRCC, Aldesleukin was granted FDA approval for the treatment of adults with metastatic melanoma in 1998.[8] The efficacy data supporting this indication came from a pooled analysis of 8 clinical studies involving 270 patients treated with single-agent Proleukin. In this cohort, the ORR was 16% (43 of 270 patients), which included a 6% complete response rate (17 patients) and a 10% partial response rate (26 patients).[1] An independent consecutive series of patients treated with bolus intravenous IL-2 reported a nearly identical ORR of 16.3%.[27]

As with mRCC, the defining characteristic of the responses in melanoma is their durability. A small number of patients can experience a complete regression of their disease that persists for seven or more years after treatment has ended, an outcome that was virtually unheard of with conventional chemotherapy.[8] Responses to Aldesleukin have been observed across a range of metastatic sites, including both visceral locations (e.g., lung, liver, adrenal) and non-visceral sites (e.g., lymph nodes, soft tissue, subcutaneous). Efficacy has also been demonstrated in patients with bulky individual lesions and a high overall cumulative tumor burden.[1] One analysis noted that response was more frequent in patients whose metastases were confined to subcutaneous tissues.[27]

4.3. Compendial Use: Chronic Graft-versus-Host Disease (cGVHD)

The application of Aldesleukin in chronic graft-versus-host disease (cGVHD) represents a therapeutic inversion of its oncologic use, showcasing a sophisticated understanding of its dose-dependent immunomodulatory effects. In this context, the goal is not high-dose immune stimulation but rather targeted immune suppression. This is achieved using low-dose subcutaneous Aldesleukin (e.g., 1 million  daily), which leverages the differential IL-2R affinity on T-cell subsets. At these low concentrations, the drug preferentially binds to the high-affinity IL-2R constitutively expressed on immunosuppressive regulatory T-cells (), leading to their selective expansion.[22] By augmenting the  compartment, this therapy helps to re-establish immune tolerance and control the autoimmune-like pathology that drives cGVHD.

This off-label use is supported by major clinical guidelines. The National Comprehensive Cancer Network (NCCN) provides a category 2A recommendation for the use of Aldesleukin as additional therapy, in conjunction with systemic corticosteroids, for patients with steroid-refractory cGVHD.[28] Clinical studies, including those in pediatric populations, have demonstrated high response rates. A retrospective review of pediatric patients treated with low-dose IL-2 showed an impressive ORR of 85% (including 5 CRs and 6 PRs).[22] This approach has proven to be a well-tolerated and potent steroid-sparing agent, offering a valuable therapeutic option for a difficult-to-treat condition.[22]

4.4. Compendial Use: High-Risk Neuroblastoma

In the treatment of pediatric high-risk neuroblastoma, Aldesleukin is not used as a monotherapy but serves as a critical synergistic component within complex, multi-modal immunotherapy regimens administered after consolidation therapy (high-dose chemotherapy and stem cell transplant).[17] Its role is prominently defined in protocols developed by the Children's Oncology Group (COG), such as the landmark trial COG-ANBL0032 (NCT00026312).[33]

In this therapeutic framework, Aldesleukin is administered in combination with the anti-GD2 monoclonal antibody dinutuximab and granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim).[33] The rationale for this combination is to maximize the efficacy of dinutuximab. Dinutuximab targets the GD2 antigen on neuroblastoma cells and works primarily through antibody-dependent cell-mediated cytotoxicity (ADCC), a process in which NK cells are the primary immune effectors. Aldesleukin is administered as a continuous IV infusion during specific cycles of the immunotherapy regimen (courses 2 and 4 in the ANBL0032 protocol) with the explicit goal of stimulating the proliferation and enhancing the cytotoxic activity of these NK cells, thereby potentiating the anti-tumor effect of the monoclonal antibody.[33] The evolution of Aldesleukin's use from a high-dose "sledgehammer" in adult oncology to a more nuanced, mechanistically targeted component in pediatric combination therapy demonstrates a significant maturation in the clinical understanding of how to harness its specific biological effects.

Table 2: Summary of Clinical Efficacy in Key Indications

Indication	Objective Response Rate (ORR)	Complete Response (CR) Rate	Key Efficacy Endpoint	Supporting Data
Metastatic RCC	25% (Select Trial)	2.5% (Select Trial)	Durable remission (11% PFS at 3 yrs)	23
Metastatic Melanoma	16%	6%	Durable remission (responses >7 years)	1
Steroid-Refractory cGVHD	~85% (pediatric)	~38% (pediatric)	Steroid-sparing effect, restoration of tolerance	22
High-Risk Neuroblastoma	N/A (combination use)	N/A (combination use)	Improved Event-Free Survival (in combination)	33

Section 5: Dosing, Administration, and Patient Management

5.1. High-Dose Intravenous Regimen for Oncology (mRCC, Melanoma)

The administration protocol for high-dose Aldesleukin is less a standard medication order and more a comprehensive clinical management plan designed to maximize efficacy while managing profound toxicity.

• Standard Dose: The recommended dose is 600,000 International Units (IU) per kilogram of body weight (equivalent to 0.037 mg/kg).[1] This dose is administered as a 15-minute intravenous infusion every 8 hours.
• Treatment Course Structure: A single course of therapy consists of two 5-day treatment cycles separated by a 9-day rest period. Within each 5-day cycle, a maximum of 14 doses are scheduled to be administered (one dose every 8 hours). Therefore, a full treatment course comprises a maximum of 28 doses.[1] It is a critical and expected feature of this therapy that most patients will not receive all scheduled doses. Due to the development of dose-limiting toxicities, doses are frequently withheld; in clinical trials, patients with melanoma and mRCC received a median of 18 to 20 doses per course, respectively.[1]
• Retreatment Criteria: Patients are evaluated for response approximately 4 weeks after the completion of a course. Additional courses of therapy are considered only for patients who demonstrate some evidence of tumor shrinkage or stable disease. Each treatment course must be separated by a rest period of at least 7 weeks from the date of hospital discharge.[17]
• Mandatory Clinical Setting: The administration of high-dose Aldesleukin carries significant risks of life-threatening complications. Consequently, it must be administered in a hospital setting under the direct supervision of a qualified physician experienced in the use of anticancer agents. Furthermore, the facility must have an intensive care unit (ICU) and specialists skilled in cardiopulmonary or intensive care medicine readily available to manage severe adverse reactions.[1]

5.2. Regimens for Compendial Uses

The dosing and administration of Aldesleukin for its off-label indications differ significantly from the high-dose oncology regimen, reflecting their distinct therapeutic goals.

• Chronic GVHD: The regimen is designed for immunosuppression via  expansion. It typically involves low-dose subcutaneous administration, with a common dose being 1 million  given daily for a defined period, such as 12 weeks, followed by a treatment break.[22]
• Neuroblastoma (ANBL0032 Protocol): The regimen is designed to synergize with dinutuximab. Aldesleukin is administered as a continuous intravenous infusion during courses 2 and 4 of the 5-cycle immunotherapy regimen. The dosing is 3 million ()  for the first 4 days (96 hours), followed immediately by 4.5 million ()  for the next 4 days (96 hours).[33]

5.3. Patient Selection and Pre-Treatment Evaluation

Stringent patient selection is mandatory and is the most critical first step in mitigating the risks of Aldesleukin therapy.[1] Only patients with an excellent Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 should be considered, as they have been shown to have better response rates and lower toxicity.[1]

A comprehensive pre-treatment evaluation is required to rule out significant underlying organ dysfunction, which is an absolute contraindication. This screening must include:

• Cardiac Function: A normal thallium stress test or equivalent cardiac evaluation to rule out significant coronary artery disease or myocardial dysfunction.[1]
• Pulmonary Function: Formal pulmonary function tests (PFTs) must demonstrate adequate reserve, typically defined as a forced expiratory volume in 1 second () of greater than 2 liters or  of the predicted value for height and age.[6]
• Renal Function: Baseline renal function must be adequate, with a serum creatinine of  mg/dL.[16]
• Infection Status: Any pre-existing bacterial infections must be fully and adequately treated prior to initiating Aldesleukin therapy due to the increased risk of disseminated infection.[1]

5.4. Monitoring and Supportive Care

The clinical management of a patient receiving high-dose Aldesleukin is intensive and proactive, focused on anticipating and managing expected toxicities.

• Intensive Monitoring: Patients require daily laboratory assessments, including complete blood counts and comprehensive metabolic panels, to monitor hematologic status and organ function.[4] Vital signs, fluid intake and output, and daily weights must be meticulously tracked to detect the early signs of Capillary Leak Syndrome, such as hypotension and fluid retention.[16]
• Prophylactic and Supportive Care: A regimen of supportive care medications is standard practice to manage the common and predictable side effects. This typically includes:
• Fever and Rigors: Standard antipyretics like acetaminophen are used to control fever. Severe rigors (chills) associated with fever can be managed with meperidine.[1]
• Gastrointestinal Effects: Antiemetics are given to control nausea and vomiting, and antidiarrheals are used as needed. H2 antagonists or proton pump inhibitors are often administered for prophylaxis against gastrointestinal irritation and bleeding.[1]
• Oral Care: Meticulous oral hygiene is essential to prevent or mitigate stomatitis (mouth sores). This includes using a soft-bristle toothbrush and avoiding mouthwashes that contain alcohol. Rinsing with a simple baking soda and/or salt solution is recommended.[4]
• Nutritional Support: Loss of appetite and taste changes are common. Patients are encouraged to eat small, frequent meals and may require nutritional supplements to maintain caloric intake.[5]

This entire protocol underscores that the process is designed to push the patient to the brink of tolerable toxicity to maximize the chance of a powerful immune response, requiring a highly experienced clinical team to navigate the fine line between efficacy and irreversible harm.

Section 6: Comprehensive Safety Profile and Risk Management

The safety profile of Aldesleukin is not a list of disparate side effects but rather a description of a single, systemic, and predictable process: a global, cytokine-mediated inflammatory response syndrome. Nearly all major toxicities are downstream manifestations of this core mechanistic action. The management of these toxicities is the central challenge of the therapy.

6.1. Boxed Warnings and Life-Threatening Toxicities

6.1.1. Capillary Leak Syndrome (CLS)

Capillary Leak Syndrome is the hallmark toxicity of high-dose Aldesleukin and is a direct consequence of the systemic cytokine cascade it induces.

• Pathophysiology: CLS is characterized by a loss of vascular tone and a marked increase in capillary permeability. This allows plasma proteins (like albumin) and fluid to leak from the intravascular compartment into the extravascular space.[1] This process can begin almost immediately after treatment is initiated.[16]
• Clinical Manifestations: The clinical sequelae of this fluid shift are severe and multi-systemic. Key manifestations include severe hypotension, generalized edema, weight gain, ascites, and pleural or pericardial effusions. The resulting intravascular volume depletion and hypoperfusion can lead to end-organ damage, including myocardial infarction, respiratory insufficiency requiring intubation, renal failure, and ultimately, death.[1]
• Management: Management of CLS requires intensive monitoring, often in an ICU setting. It involves a delicate balance of administering intravenous fluids to support intravascular volume and blood pressure, while trying to avoid exacerbating the extravascular edema and pulmonary compromise. Vasopressor agents, such as dopamine or phenylephrine, are frequently required to maintain blood pressure and ensure adequate organ perfusion.[16] Aldesleukin doses must be withheld immediately for any signs of organ hypoperfusion, such as altered mental status, reduced urine output, or a systolic blood pressure below 90 mm Hg.[16]

6.1.2. Neurologic Toxicity

Aldesleukin can cause a wide spectrum of neurologic toxicities, which may be severe, life-threatening, and in some cases, result in permanent deficits.

• Spectrum of Effects: Clinical manifestations range from changes in mental status (irritability, confusion, depression) to more severe symptoms like agitation, hallucinations, speech difficulties, cortical blindness, and limb or gait ataxia.[1] In the most severe cases, patients can develop obtundation, coma, or seizures. These symptoms can worsen for several days even after the drug is discontinued before recovery begins.[6]
• Management: Close neurologic monitoring is essential. The development of moderate to severe lethargy or somnolence is a critical warning sign, and Aldesleukin administration must be withheld immediately, as continued treatment may result in coma.[1]

6.1.3. Serious Infection Risk

Treatment with Aldesleukin is associated with a significantly increased risk of severe bacterial infections.

• Mechanism: The drug impairs neutrophil function, specifically reducing their ability to migrate to sites of infection (a process called chemotaxis). This functional defect, combined with the frequent use of indwelling central venous catheters, creates a high risk for disseminated bacterial infections, including sepsis and bacterial endocarditis, even in the absence of significant neutropenia.[1]
• Management: All pre-existing bacterial infections must be fully eradicated before starting therapy. Prophylactic antibiotics (e.g., oxacillin, vancomycin) should be considered for patients with central lines.[1] Patients must be monitored vigilantly for any signs or symptoms of infection, such as fever or chills, and treated promptly with broad-spectrum antibiotics if an infection is suspected.[4]

6.2. Other Significant Adverse Reactions

• Hepatotoxicity: Mild-to-moderate elevations in serum aminotransferases (ALT) and bilirubin are extremely common, occurring in more than half of patients receiving high-dose therapy.[3] This is generally not an idiosyncratic drug-induced liver injury but rather a predictable, transient cholestasis that resembles the jaundice of sepsis. It is thought to be caused by a direct effect of IL-2 on bile transport and secretion. These elevations typically reverse rapidly upon discontinuation of the drug.[3]
• Renal Toxicity: Serious kidney toxicity, including oliguria and acute renal failure requiring dialysis, is a frequent complication. This is often a secondary consequence of the severe systemic hypotension and renal hypoperfusion caused by CLS.[6]
• Exacerbation of Autoimmune Disease: The potent, non-specific immune stimulation from Aldesleukin can trigger flares of pre-existing autoimmune diseases or lead to the new onset of inflammatory disorders. Conditions reported to be exacerbated include Crohn's disease, scleroderma, thyroiditis, inflammatory arthritis, myasthenia gravis, and vasculitis.[6]

6.3. Common Adverse Events

In addition to the life-threatening toxicities, a constellation of other adverse events is commonly experienced by patients.

• Constitutional Symptoms: A flu-like syndrome characterized by high fever, severe chills (rigors), profound fatigue, and malaise is nearly universal.[3]
• Gastrointestinal: Nausea, vomiting, and diarrhea are very common and can be severe.[3] Stomatitis (mouth and throat sores) is also frequently observed.[6]
• Dermatologic: Pruritus (itching) and various forms of skin rash, including exfoliative dermatitis, are common.[6]
• Cardiovascular: Sinus tachycardia is an expected finding, often as a compensatory response to hypotension from CLS. Supraventricular and other arrhythmias can also occur.[6]
• Hematologic: As a direct result of its mechanism of action, Aldesleukin induces profound and predictable changes in blood counts, including marked lymphocytosis, eosinophilia, and thrombocytopenia.[1]

The clinical strategy for managing this formidable array of toxicities is one of "permissive toxicity." Clinicians expect and plan for severe but reversible organ dysfunction. The goal is not to prevent all toxicity, but to manage it—to titrate the therapy by holding doses at predefined thresholds, allowing the administration of the maximum tolerated number of doses without causing irreversible harm. The fact that doses are withheld in over 90% of patients is not a sign of treatment failure but is an integral and expected part of the therapeutic process.[1]

Table 3: Major Toxicities, Monitoring, and Management

Toxicity	Key Signs/Symptoms	Required Monitoring	Management/Action Threshold
Capillary Leak Syndrome (CLS)	Hypotension, edema, weight gain, dyspnea, oliguria, hypoalbuminemia	Vitals q2-4h, daily weight, fluid intake/output, serum albumin	Withhold dose for SBP <90 mm Hg or signs of organ hypoperfusion. Administer vasopressors/fluids cautiously. 1
Neurologic Toxicity	Confusion, lethargy, somnolence, agitation, hallucinations, seizures	Frequent neurologic checks (e.g., q8h)	Withhold dose for moderate/severe lethargy or somnolence. Permanently discontinue for coma >48h or refractory seizures. 1
Serious Infection	Fever, chills, positive cultures, local signs of infection	Daily temperature, CBC with differential, blood cultures if febrile	Treat pre-existing infections. Withhold dose for active infection. Administer broad-spectrum antibiotics promptly. 6
Renal Toxicity	Oliguria, rising serum creatinine	Daily serum creatinine, urine output	Withhold dose for significant rise in creatinine or persistent oliguria. Manage hypoperfusion. 6

Section 7: Contraindications and Clinically Significant Drug Interactions

7.1. Absolute and Relative Contraindications

The high potential for severe toxicity necessitates strict contraindications to ensure patient safety.

• Absolute Contraindications: Aldesleukin is absolutely contraindicated in the following patient populations:
• Organ Allograft Recipients: Due to the potent stimulation of the immune system, there is a very high risk of inducing acute, severe rejection of the transplanted organ.[1]
• Patients with Significant Organ Impairment: Patients with pre-existing and significant cardiac, pulmonary, renal, or hepatic impairment, as defined by the mandatory pre-treatment screening tests, are not candidates for therapy.[6]
• Hypersensitivity: Patients with a known history of severe hypersensitivity to Aldesleukin or any of its components are contraindicated.[6]
• Contraindications for Retreatment: Patients who have previously experienced certain severe, life-threatening toxicities during a prior course of Aldesleukin should not be retreated. These toxicities include sustained ventricular tachycardia, uncontrolled cardiac arrhythmias, coma or toxic psychosis lasting more than 48 hours, repetitive or difficult-to-control seizures, and gastrointestinal bleeding or perforation requiring surgery.[1]

7.2. Clinically Significant Drug-Drug Interactions

The list of potential drug interactions with Aldesleukin is primarily driven by the risk of synergistic or additive toxicity. Because Aldesleukin places significant stress on multiple organ systems, the co-administration of any drug that also affects these systems can remove any remaining physiological safety margin, leading to an exponential increase in the risk of organ failure.

• Corticosteroids: This is a critical pharmacodynamic interaction. Concomitant use of glucocorticoids (e.g., dexamethasone, prednisone) should be avoided. As potent immunosuppressants, they may directly counteract and diminish the intended anti-tumor efficacy of Aldesleukin.[38]
• Drugs Potentiating Organ Toxicity:
• Nephrotoxic Agents: Co-administration of other drugs known to cause kidney damage (e.g., aminoglycoside antibiotics, NSAIDs, cisplatin) may dramatically increase the risk of severe renal failure.[6]
• Hepatotoxic Agents: The use of other potentially hepatotoxic drugs (e.g., high-dose acetaminophen, methotrexate, certain antifungal agents) may exacerbate the liver dysfunction commonly seen with Aldesleukin.[16]
• Cardiotoxic and Myelosuppressive Agents: Drugs with known cardiac or bone marrow toxicity should be used with extreme caution.
• Hypotensive Agents: Antihypertensive medications can severely worsen the hypotension associated with CLS. It is standard practice to hold these medications during the period of Aldesleukin administration to avoid profound, refractory hypotension.[4]
• Iodinated Contrast Media: There have been reports of delayed hypersensitivity reactions to iodinated radiologic contrast media in patients who have previously been treated with Aldesleukin. The mechanism is not fully understood but may relate to long-term immune system priming.[21]

Effective management of Aldesleukin therapy requires a thorough medication reconciliation and a proactive plan to temporarily discontinue non-essential medications that could contribute to toxicity during the treatment period.

Section 8: Regulatory Landscape

8.1. U.S. Food and Drug Administration (FDA) History

Aldesleukin (Proleukin) has a well-documented regulatory history in the United States, marking it as one of the earliest approved immunotherapies for cancer.

• Metastatic Renal Cell Carcinoma (mRCC): The drug first received orphan drug designation for this indication on September 14, 1988. Following review of clinical trial data, full marketing approval for the treatment of adults with mRCC was granted by the FDA on May 5, 1992.[11]
• Metastatic Melanoma: Subsequently, the sponsor sought to expand the drug's label. It received orphan drug designation for the treatment of metastatic melanoma on September 10, 1996. The FDA granted full marketing approval for this second indication on January 9, 1998.[26]

8.2. Therapeutic Goods Administration (TGA) Status in Australia

The regulatory status of Aldesleukin in Australia is less clear-cut and appears to have evolved over time, reflecting the challenges that highly specialized, high-risk drugs can pose to standard regulatory frameworks.

• Formal Approved Indication and Route: A key publication in the Australian Prescriber from April 2000 reported that Proleukin (sponsored by CSL at the time) was approved by the TGA for the indication of renal cell carcinoma.[18] Critically, this same source states that due to the severe adverse effects associated with intravenous administration, the drug was only approved for subcutaneous injection in Australia at that time.[18] This initial, cautious approval of a less toxic (though also less established) route reflects the profound safety concerns surrounding the drug.
• Evidence of Evolved Clinical Practice: Despite this dated information on the formal approval, more recent documents suggest that clinical practice in Australia has evolved to include other routes and indications, likely through specialized regulatory pathways. A 2021 report from the TGA's Special Access Scheme (SAS) documents instances of Aldesleukin being supplied via intravenous and intralesional routes for the treatment of melanoma and Graft versus Host Disease.[45] The SAS provides a legal and ethical pathway for medical specialists to access therapeutic goods that are not included on the Australian Register of Therapeutic Goods (ARTG) for individual patients.
• Conclusion on TGA Status: There appears to be a significant discrepancy between the last widely published formal approval (subcutaneous for RCC in 2000) and current specialist clinical practice. A clear, updated public entry for Proleukin on the ARTG was not readily identified in the available materials.[46] The use of the drug via more toxic intravenous routes under the SAS suggests that expert clinical opinion has evolved to align with the international standard of care (high-dose IV for oncology), recognizing that the potential for a cure in select patients justifies the risk, provided it is managed within an expert hospital setting. This situation highlights a bifurcation in the drug's regulatory status: a narrow, historical formal approval coexisting with a broader, specialist-driven practical application under specific access provisions.

Section 9: Synthesis and Concluding Remarks

9.1. Aldesleukin in the Modern Immunotherapy Era

In the contemporary landscape of oncology, which is dominated by newer, better-tolerated immunotherapies such as anti-PD-1 (e.g., pembrolizumab, nivolumab) and anti-CTLA-4 (e.g., ipilimumab) checkpoint inhibitors, the role of high-dose Aldesleukin has necessarily shifted.[8] These modern agents have become the standard of care for metastatic melanoma and renal cell carcinoma due to their superior safety profiles and, in many cases, higher overall response rates.

However, Aldesleukin retains a unique and critical advantage that ensures its continued, albeit niche, relevance: its unparalleled ability to induce durable, complete, and potentially curative remissions in a subset of patients.[8] While checkpoint inhibitors have improved survival for many, the "tail on the curve" representing long-term, treatment-free survivors first established by HD IL-2 remains a benchmark in immuno-oncology. The legacy of Aldesleukin is therefore not just as a historical drug, but as the enduring proof-of-concept for the curative potential of immunotherapy. It established the foundational principle that the immune system, if sufficiently and powerfully stimulated, could eradicate even widely metastatic cancer.

This enduring potential for a cure means that Aldesleukin remains a viable, though typically second-line or subsequent, therapeutic option. It is reserved for a highly select group of young, physically fit patients with mRCC or melanoma who have an excellent performance status, who are seeking a chance at a curative outcome, and who are fully informed and willing to tolerate the significant and predictable toxicities of the treatment.[29]

9.2. Clinical Recommendations and Future Directions

The enduring relevance of Aldesleukin also lies in its mechanistic distinction from modern immunotherapies. Checkpoint inhibitors function primarily by "releasing the brakes" on a pre-existing, tumor-specific T-cell response that has often become suppressed or exhausted within the tumor microenvironment. In contrast, Aldesleukin works by inducing a massive, non-specific proliferation of a broad range of lymphocytes, effectively "stepping on the gas" to generate a new and overwhelming immune assault. This fundamental difference in mechanism may explain why it can be effective in patients who have failed checkpoint inhibitor therapy and why its responses, when they occur, can be so profound and complete. It remains in the therapeutic armamentarium because it offers a fundamentally different, non-cross-resistant immunological strategy to attack the cancer.

• The Primacy of Patient Selection: The key to optimizing Aldesleukin's therapeutic index is, and will remain, stringent and meticulous patient selection. Only patients with excellent performance status and confirmed normal end-organ function should be considered for this intensive therapy.
• Future Research Directions:
• Combination Therapies: Research continues to explore rational combination strategies, particularly with checkpoint inhibitors. The theoretical synergy—using IL-2 to expand the T-cell population and a checkpoint inhibitor to ensure those T-cells remain functional—is compelling and the subject of ongoing clinical trials.[9]
• Biomarker Discovery: A critical unmet need is the development of reliable predictive biomarkers to identify, in advance, the 15-25% of patients who are likely to respond. Such a tool would be invaluable in sparing non-responders from the rigors and risks of the therapy. The observed association between response and tumor PD-L1 expression is a promising lead that requires independent validation.[23]
• Next-Generation Cytokines: The ultimate goal of cytokine research is the development of novel IL-2 analogues or other engineered cytokines that can successfully decouple the potent anti-tumor effects from the severe toxicities like Capillary Leak Syndrome. Such an agent would represent a major advance in immuno-oncology.

Works cited

1. Proleukin (aldesleukin) injection label - accessdata.fda.gov, accessed October 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf
2. Proleukin - NEW ZEALAND DATA SHEET, accessed October 12, 2025, https://www.medsafe.govt.nz/profs/datasheet/p/Proleukininj.pdf
3. Aldesleukin - LiverTox - NCBI Bookshelf, accessed October 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548091/
4. Proleukin (aldesleukin): Uses, Side Effects, Dosage & Reviews - GoodRx, accessed October 12, 2025, https://www.goodrx.com/proleukin/what-is
5. Interleukin-2 (Proleukin®, IL-2, Aldesleukin) | OncoLink, accessed October 12, 2025, https://www.oncolink.org/cancer-treatment/oncolink-rx/interleukin-2-proleukin-R-il-2-aldesleukin
6. Aldesleukin | Drug Lookup | Pediatric Care Online, accessed October 12, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5593/Aldesleukin
7. Aldesleukin (intravenous route) - Side effects & uses - Mayo Clinic, accessed October 12, 2025, https://www.mayoclinic.org/drugs-supplements/aldesleukin-intravenous-route/description/drg-20061519
8. Interleukin IL-2 (Aldesleukin) Proleukin Overview for Melanoma Treatment - MRA, accessed October 12, 2025, https://www.curemelanoma.org/patient-eng/melanoma-treatment/options/interleukin-2-il-2-aldesleukin-proleukin
9. What is the mechanism of Aldesleukin? - Patsnap Synapse, accessed October 12, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-aldesleukin
10. CIS - Aldesleukin - Clinical Immunology Society, accessed October 12, 2025, https://clinimmsoc.org/Table-of-Compounds/Aldesleukin.htm
11. Search Orphan Drug Designations and Approvals - FDA, accessed October 12, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=29088
12. Update on use of aldesleukin for treatment of high-risk metastatic melanoma - PMC, accessed October 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4918260/
13. (PDF) Update on use of aldesleukin for treatment of high-risk metastatic melanoma, accessed October 12, 2025, https://www.researchgate.net/publication/272745949_Update_on_use_of_aldesleukin_for_treatment_of_high-risk_metastatic_melanoma
14. Definition of aldesleukin - NCI Drug Dictionary - NCI, accessed October 12, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aldesleukin
15. Aldesleukin - NCI, accessed October 12, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/aldesleukin
16. How to order PROLEUKIN® (aldesleukin) Recombinant IL-2, accessed October 12, 2025, https://www.proleukin.com/
17. Aldesleukin (Proleukin) - Medical Clinical Policy Bulletins - Aetna, accessed October 12, 2025, https://www.aetna.com/cpb/medical/data/1_99/0024.html
18. Aldesleukin - Australian Prescriber - Therapeutic Guidelines, accessed October 12, 2025, https://australianprescriber.tg.org.au/articles/aldesleukin.html
19. www.cancer.gov, accessed October 12, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aldesleukin#:~:text=Aldesleukin%20binds%20to%20and%20activates,in%20an%20activated%20receptor%20complex.
20. DRUG NAME: Aldesleukin - BC Cancer, accessed October 12, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Aldesleukin_monograph.pdf
21. aldesleukin - Cancer Care Ontario, accessed October 12, 2025, https://www.cancercareontario.ca/en/system/files_force/aldesleukin.pdf?download=1
22. Real-world experience with low-dose IL-2 for children and young ..., accessed October 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10448423/
23. The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma - PMC - PubMed Central, accessed October 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4315731/
24. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma - PubMed, accessed October 12, 2025, https://pubmed.ncbi.nlm.nih.gov/25424850/
25. The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively ..., accessed October 12, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315731/
26. Search Orphan Drug Designations and Approvals - accessdata.fda ..., accessed October 12, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=100696
27. Correlates of response to IL-2 therapy in patients treated for ..., accessed October 12, 2025, https://pubmed.ncbi.nlm.nih.gov/9166506/
28. Proleukin (aldesleukin) - Louisiana Department of Health, accessed October 12, 2025, https://ldh.la.gov/assets/medicaid/MCPP/2.23.21/Proleukin9.21.20ING-CC-0175.pdf
29. Oncology (Injectable) - Proleukin UM Medical Policy.docx - CareSource, accessed October 12, 2025, https://www.caresource.com/documents/medicare-multi-policy-pharmacy-proleukin-20250326.pdf
30. Aldesleukin (Proleukin®) - NantHealth, accessed October 12, 2025, https://info.nanthealth.com/hubfs/clinical-guidelines/Medical%20Oncology/Aldesleukin%20-%20NH.pdf
31. Proleukin (aldesleukin), accessed October 12, 2025, https://files.providernews.anthem.com/1827/ING-CC-0175.pdf
32. Aldesleukin (Proleukin®, IL-2, Interleukin) - Blue Shield of California, accessed October 12, 2025, https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/2023/January/PRV_MP_Aldesleukin_ProleukinIL2Interleukin_MCAL.pdf
33. Study Details | Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | ClinicalTrials.gov, accessed October 12, 2025, https://clinicaltrials.gov/study/NCT00026312?term=NCT00026312&rank=1
34. Study Details | NCT00026312 | Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | ClinicalTrials.gov, accessed October 12, 2025, https://www.clinicaltrials.gov/study/NCT00026312
35. Neuroblastoma Clinical Trials - Mayo Clinic Research, accessed October 12, 2025, https://www.mayo.edu/research/clinical-trials/diseases-conditions/neuroblastoma
36. Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-risk Neuroblastoma: Children's Oncology Group Study ANBL0032 - PMC, accessed October 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8046731/
37. Aldesleukin: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 12, 2025, https://www.rxlist.com/aldesleukin/generic-drug.htm
38. Interleukin 2, Proleukin (aldesleukin) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed October 12, 2025, https://reference.medscape.com/drug/interleukin-2-proleukin-aldesleukin-342203
39. Proleukin 2080-A SGM P2021.pdf - SPECIALTY GUIDELINE MANAGEMENT, accessed October 12, 2025, https://www.shpnc.gov/documents/files/proleukin/open
40. Aldesleukin: MedlinePlus Drug Information, accessed October 12, 2025, https://medlineplus.gov/druginfo/meds/a692009.html
41. Proleukin® (aldesleukin, IL-2) - Gateway PA, accessed October 12, 2025, https://gatewaypa.com/api/policydisplay/download?key=PolicyItems/Clinical_Existing/Pdfs/WellFirst%20Health%20NonOncology%20Clinical%20Guidelines/WFH-Proleukin-aldesleukin,%20IL-2.pdf
42. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014, accessed October 12, 2025, https://jitc.bmj.com/content/2/1/26
43. Aldesleukin: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 12, 2025, https://go.drugbank.com/drugs/DB00041
44. CBER Approval Letter, supplement for Aldesleukin, new indication for use in adults with metastatic melanoma, Chiron Corporation, Emeryville, CA - accessdata.fda.gov, accessed October 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/aldechi010998L.htm
45. SAS pathway, accessed October 12, 2025, https://www.tga.gov.au/sites/default/files/2025-04/Document%201_0.XLSX
46. Australian Register of Therapeutic Goods (ARTG), accessed October 12, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
47. Therapeutic Goods Administration (TGA) | Australian Government Department of Health, Disability and Ageing, accessed October 12, 2025, https://www.tga.gov.au/
48. Product Information (PI) | Therapeutic Goods Administration (TGA), accessed October 12, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg/product-information-pi
49. Full article: An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma - Taylor & Francis Online, accessed October 12, 2025, https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1984059